SCHEMBL864908

SCHEMBL864908

Cc1cc(N)c(NCCCCCCC(=O)OC(C)(C)C)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HDAC8 Q9BY41 1/20 0.40
EPHX2 P34913 1/20 0.39
GUCY1A1 Q02108 1/20 0.37
GUCY1B1 Q02153 1/20 0.37
PTGER4 P35408 1/20 0.36
MGLL Q99685 1/20 0.36
HDAC3 O15379 3/20 0.35
PRSS1 P07477 4/20 0.35
NQO2 P16083 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
BRD4 O60885 1/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL864853 0.90 KDM4E (0.46) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL865614 0.86 KDM4E (0.43) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL30289439 0.81 KDM4E (0.47) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL864351 0.81 KDM4E (0.47) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL866327 0.81 MAPT (0.49) KDM4EALDH1A1MAPTPRSS1
SCHEMBL22511996 0.81 HDAC3 (0.51) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL28423866 0.79 KDM4E (0.45) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL13496382 0.77 GUCY1A1 (0.58) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL865112 0.75 ALDH1A1 (0.48) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL865590 0.75 CYP4F2 (0.49) KDM4EALDH1A1GAAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077781-A1 FLAVIN DERIVATIVES GADWOOD ROBERT (US) 2012-03-29 US disclosed
US-20120077781-A1 FLAVIN DERIVATIVES GADWOOD ROBERT (US) 2012-03-29 US disclosed
US-20120077781-A1 FLAVIN DERIVATIVES GADWOOD ROBERT (US) 2012-03-29 US disclosed
EP-2320734-A1 FLAVIN DERIVATIVES BioRelix, Inc. (US) 2011-05-18 EP disclosed
WO-2010019208-A1 FLAVIN DERIVATIVES BIORELIX PHARMACEUTICALS, INC. (US) 2010-02-18 WO disclosed
WO-2010019208-A1 FLAVIN DERIVATIVES BIORELIX PHARMACEUTICALS, INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077781-A1 FLAVIN DERIVATIVES BLVRB, FLAD1, FDPS KDM4E 1942/4885ALDH1A1 807/4885GAA 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.